Related Experiment Video
Updated: Mar 6, 2026
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
Alternative Biomarkers for Combined Biology
Yong-Hyun Kim1, Jennifer Kirsop2, Wai Hong Wilson Tang3
1Department of Cardiovascular Medicine, Kaufman Center for Heart Failure, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA; Cardiovascular Medicine, Korea University College of Medicine, Korea University Medical Center Ansan Hospital, 123 Jeokgeum-ro, Ansan-si 15355, Korea.
Detecting chemotherapy-related cardiac dysfunction (CRCD) early is crucial. Current biomarkers like troponin have limitations, driving research into more sensitive alternatives for better cancer treatment outcomes.
Area of Science:
- Cardiology
- Oncology
- Biomarker Research
Background:
- Chemotherapy-related cardiac dysfunction (CRCD) poses a significant clinical challenge, often leading to hesitation in using vital cardiotoxic agents like anthracyclines and certain protein kinase inhibitors.
- Early detection and intervention are key strategies to mitigate CRCD, necessitating reliable monitoring methods.
- Current biomarkers, including cardiac troponin and natriuretic peptide, exhibit inconsistencies in predicting CRCD, highlighting a critical need for improved diagnostic tools.
Purpose of the Study:
- To review the mechanisms underlying CRCD.
- To examine the efficacy and limitations of traditional biomarkers for CRCD monitoring.
- To explore novel biomarkers with enhanced sensitivity and accuracy for early CRCD detection.
Main Methods:
- Literature review of CRCD mechanisms.
- Analysis of studies on traditional biomarkers (cardiac troponin, natriuretic peptide).
- Investigation into emerging alternative biomarkers for cardiotoxicity.
Main Results:
- Traditional biomarkers show variable predictability for CRCD.
- Significant research is underway to identify more sensitive and accurate biomarkers.
- Understanding CRCD mechanisms is essential for biomarker development.
Conclusions:
- There is a pressing need for superior biomarkers to enable timely intervention and continued use of essential cancer therapies.
- Future research should focus on validating novel biomarkers for CRCD.
- Improved biomarker strategies can enhance patient outcomes in oncology.
